Search | Clinical Trials Finder

Conditions: Anemia in Pregnancy, Pre-eclampsia
Interventions: Neevo®, Prenatal vitamins; Other
Lead sponsor: Pamlab, L.L.C.; Industry
Eligibility: 21 Years to 39 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 3
States / cities: Chickasha, Oklahoma • Norman, Oklahoma

Conditions: Iron-deficiency, Iron Deficiency Anemia, Iron Deficiency (Without Anemia)
Interventions: Partially hydrolyzed guar gum + bifidobacterium lactis, Partially hydrolyzed guar gum, Maltodextrin; Dietary Supplement
Lead sponsor: King's College; Other
Eligibility: 18 Years to 35 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Wilkes-Barre, Pennsylvania

Conditions: Iron Deficiency Anemia
Interventions: Iron Supplement, multivitamin; Dietary Supplement
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 24 Weeks to 32 Weeks
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Iron Deficiency Anemia, Iron-deficiency
Interventions: 95% condensed proanthocyanidins from grape seed extract; Dietary Supplement
Lead sponsor: Kansas State University; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Manhattan, Kansas

Conditions: Epithelial Ovarian Cancer, Anemia, Iron Deficiency Anemia
Interventions: Iron Sucrose; Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older · Female only
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Iron Deficiency, Anemia
Interventions: Fer-in-Sol, control; Dietary Supplement · Other
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 4 Weeks to 9 Months
Enrollment: 219 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Iron Deficiency Anaemia, Iron Deficiency Anemia
Interventions: Iron isomaltoside/ferric derisomaltose, Ferric carboxymaltose; Drug
Lead sponsor: Pharmacosmos A/S; Industry
Eligibility: 18 Years and older
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 15
States / cities: Muscle Shoals, Alabama • Doral, Florida • Miami, Florida + 11 more

Conditions: Chronic Kidney Disease, Iron Deficiency, Anemia
Interventions: ferric citrate, ferrous sulfate; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Iron Deficiency Anemia
Interventions: Ferric Carboxymaltose (FCM), Ferrous Sulfate Tablets, IV Iron (standard of care); Drug
Lead sponsor: American Regent, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 997 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Norristown, Pennsylvania

Conditions: Iron Deficiency Anemia
Interventions: Ferric carboxymaltose; Drug
Lead sponsor: American Regent, Inc.; Industry
Eligibility: 1 Year to 18 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 2
States / cities: Miami, Florida • Miami Springs, Florida

Conditions: Anemia
Interventions: Iron (ferrous sulfate); Drug
Lead sponsor: Emory University; Other
Eligibility: Up to 2 Months
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Anemia
Interventions: Ferric Carboxymaltose, Iron Dextran; Drug
Lead sponsor: American Regent, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Norristown, Pennsylvania

Conditions: Iron Deficiency (Without Anemia)
Interventions: Liquid Placebo Supplementation, Liquid Iron Supplement (Blood Builder ®); Dietary Supplement
Lead sponsor: Applied Science & Performance Institute; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 95 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Iron-deficiency
Interventions: Iron Sulfate; Drug
Lead sponsor: Ann & Robert H Lurie Children's Hospital of Chicago; Other
Eligibility: 7 Days to 4 Weeks
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Heart Failure, Iron-deficiency
Interventions: Ferric Carboxymaltose, Placebo; Drug
Lead sponsor: American Regent, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 3,065 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 188
States / cities: Alexander City, Alabama • Auburn, Alabama • Mobile, Alabama + 157 more

Conditions: Anemia, Iron Deficiency Anemia
Interventions: Treatment with oral sucrosomial iron, Treatment with intravenous iron; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Hookworm Infection, Hookworm Disease
Interventions: 10 μg Na-GST-1/Alhydrogel, 30 μg Na-GST-1/Alhydrogel, 100 μg Na-GST-1/Alhydrogel, 10 μg Na-GST-1/Alhydrogel/GLA-AF (1 μg), 30 μg Na-GST-1/Alhydrogel/GLA-AF (1 μg), 30 μg Na-GST-1/Alhydrogel/GLA-AF (5 μg), 100 μg Na-GST-1/Alhydrogel/GLA-AF (5 μg); Biological
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 45 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Anemia
Interventions: Ferric Carboxymaltose, Standard Medical Care (SMC); Drug
Lead sponsor: American Regent, Inc.; Industry
Eligibility: Female only
Enrollment: 2,018 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Norristown, Pennsylvania

Conditions: Iron Deficiency Anaemia, Iron Deficiency Anemia, Chronic Kidney Disease
Interventions: Iron isomaltoside/ferric derisomaltose, Iron sucrose; Drug
Lead sponsor: Pharmacosmos A/S; Industry
Eligibility: 18 Years and older
Enrollment: 1,538 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 141
States / cities: Huntsville, Alabama • Little Rock, Arkansas • Chula Vista, California + 96 more

Conditions: Anemia
Interventions: Sodium ferric gluconate, ferrous sulfate, standard of care; Drug
Lead sponsor: Watson Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 32
States / cities: Bakersfield, California • Chula Vista, California • Long Beach, California + 29 more

Conditions: Anemia
Interventions: VIT-45, Placebo; Drug
Lead sponsor: American Regent, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 594 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Norristown, Pennsylvania

Conditions: CKD, Chronic Kidney Diseases, Hepcidin, Ergocalciferol, Vitamin D, Iron-deficiency, Anemia
Interventions: Ergocalciferol 50000 UNT, Placebo; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Hereditary Hemorrhagic Telangiectasia
Interventions: Bevacizumab (Avastin®); Drug
Lead sponsor: Hanny Al-Samkari, MD; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Anemia, Iron Deficiency
Interventions: Ferrous sulphate drops with vitamins A, D, and C, Ferrous fumarate sprinkles with vitamins and minerals; Drug
Lead sponsor: Centers for Disease Control and Prevention; Federal
Eligibility: 5 Months to 7 Months
Enrollment: 128 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 2
States / cities: Boston, Massachusetts

Search by objective public record fields.

A Retrospective Analysis of Neevo® and NeevoDHA® Compared to a Standard Prenatal Vitamin in Anemia During Pregnancy

Improving the Iron Status of Athletes With Pre-, Pro- and Synbiotics

Trial Comparing Iron Supplementation Versus Routine Iron Intake in Very Low Birth Weight Infants

Multiple Daily Condensed Tannin Supplementation and Iron Bioavailability: The Tannin Dose Response Trial

Evaluation and Treatment of Iron Deficiency in Ovarian Cancer Patients

Prevention of Iron Deficiency in Breastfed Infants

Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose or Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia

Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency

Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia (IDA)

Efficacy and Safety of Intravenous Ferric Carboxymaltose in Pediatric Patients With Iron Deficiency Anemia and Unsatisfactory Response Oral Iron Under Study Protocol 1VIT17044

Iron Prophylaxis for Anemia in Infants With Cyanotic Congenital Heart Disease

Safety and Tolerability of Ferric Carboxymaltose (FCM) Versus Iron Dextran in Treating Iron Deficiency Anemia

Efficacy of a Low Dose, Oral, Liquid Iron Supplement on Restoring Inadequate Blood Iron to Normal Levels

Iron Supplementation and Neurodevelopmental Outcome in ELGANs

Randomized Placebo-controlled Trial of FCM as Treatment for Heart Failure With Iron Deficiency / and Sub-Study

Sucrosomial Vs Intravenous Iron for Preoperative Anemia

Safety and Immunogenicity of a Human Hookworm Candidate Vaccine With Different Doses of a Novel Adjuvant

Safety of FCM vs. Standard of Care in Treating Iron Deficiency Anemia in Heavy Uterine Bleeding and Post Partum Patients

Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for Treatment of Iron Deficiency Anemia in Non-Dialysis-Dependent Chronic Kidney Disease

Effect of Iron Therapy as an Adjunct to Epoetin Alfa in the Anemia of Cancer Chemotherapy

Safety and Tolerability of Intravenous VIT-45 in Patients With Iron Deficiency Anemia

Effect of Ergocalciferol on Iron Metabolism in Individuals With Chronic Kidney Disease

Bevacizumab In Hereditary Hemorrhagic Telangiectasia

Adherence With Iron Sprinkles Among High-Risk Infants